CXCR4 and Miyoshi myopathy: The major advantage of the tracer is its potential use in a thera(g)nostic approach in combination with the 177Lu- or 90Y-labeled agent pentixather in progressive MM patients with CXCR4-positive tumor cells, as confirmed by a 68Ga-pentixafor PET scan.